gefitinib has been researched along with butaprost in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (butaprost) | Trials (butaprost) | Recent Studies (post-2010) (butaprost) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 161 | 0 | 46 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chun, KS; Langenbach, R; Lao, HC | 1 |
1 other study(ies) available for gefitinib and butaprost
| Article | Year |
|---|---|
The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways.
Topics: Alprostadil; Animals; Arrestins; beta-Arrestins; Cell Proliferation; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; GTP-Binding Proteins; Keratinocytes; Mice; Mitogen-Activated Protein Kinase 3; Multiprotein Complexes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Prostaglandin E, EP2 Subtype; Signal Transduction; Skin; src-Family Kinases; STAT3 Transcription Factor; Tyrphostins | 2010 |